and subsequently chemotherapy. 2, 3 The third group present with locally advanced disease and have primary tumours extending outside the prostate gland to the surrounding tissues or seminal vesicles but without spread beyond the pelvic region. With radical treatment there is good prospect of cure, and there is longstanding evidence for use of radical RT in combination with neoadjuvant and adjuvant hormone therapy 4 but it is only fairly recently that specific guidance on options for treating locally advanced disease have been published. 3 These National Institute for Health and Care Excellence (NICE) guidelines recommend offering either radical prostatectomy (RP), possibly with adjuvant radiotherapy, or radical RT with neo-adjuvant hormone therapy as treatment for men with locally advanced prostate cancer.
Given that guidelines on managing locally advanced prostate cancer have recently changed, we wanted to quantify the baseline variation in use of radical treatments for this patient group. We were particularly interested in variation between Strategic Clinical Networks (SCNs) as their remit is to improve the quality and equity of care and outcomes of their resident population. 5 Suitability for radical treatment can be affected by a number of patient characteristics including comorbidities and overall fitness for surgery, as well as their personal preferences, and so we included as many pertinent variables as possible.
Methods
We defined men with locally advanced prostate cancer as those with a T-stage of T3 or T4, which is when the primary cancer has spread beyond the capsule of the prostate; with an N-stage of 0, which is when there is no metastasis to regional lymph nodes; and M-stage of 0, where there is no metastasis to distant lymph nodes or other sites. Stage data are combined from clinical and pathological sources to form an integrated stage. Other measures of 'high-risk' disease such as grade and prostate-specific antigen (PSA) are not complete or not collected. To include these would reduce our cohort size, and they are also not referred to in the NICE guidance.
We extracted all cases of prostate cancer which satisfied these criteria from the National Cancer Registration and Analysis Service (NCRAS) data for the most recent three years available at the time: 2010-2012. The analysis was restricted to the most recent three years as data on TNM stage has historically been low, with 21% (n = 7751) of diagnoses staged in 2010, 27% (n = 10,002) in 2011, and 77% (n = 29,042) in 2012.
Data were extracted on age, ethnic group, records of RT (from the National Radiotherapy Dataset (RTDS)), record of RP (from the Hospital Episode Statistics (HES) dataset) and postcode of residence at diagnosis. The postcode of residence was used to assign men to an SCN and to quintile of income deprivation from the 2010 English Indices of Deprivation. 6 A total Charlson comorbidity score was calculated for all patients based on inpatient/day-case admissions with specific International Classification of Diseases, 10th revision (ICD-10) codes. 7 Men were grouped into three: those with no comorbidities, those with a score of 1, and those with a score of 2 or more.
Multivariable logistic regression analysis was undertaken in Microsoft Excel and STATA 13. The dependent variable was any record of radical treatment. Travel time analysis was performed in ArcMap 10.2.
Results
There were 11,995 men in NCRAS identified as being diagnosed with T3/4 N0 M0 prostate cancer in 2010-2012. The majority of men in this study (94%) had T3 disease. The relatively small proportion of T4 prostate cancer likely reflects the fact that T4 prostate cancer is more frequently associated with ⩾N1 or M1 stage disease. Three out of four diagnoses were in men aged 60-79 years. This varied between SCNs to the extent that 24% of cases diagnosed in the Wessex SCN were in men aged 80 and over, compared to 6% of cases in South East Coast SCN. There was a tendency for diagnoses to be more frequent in less-deprived areas. As with age, deprivation varied between SCNs. Thirty per cent of diagnoses in London SCN were in the most-deprived quintile, whereas 52% of cases in Thames Valley SCN were in the least-deprived quintile. The majority of cases were in men who identified as 'white', although there are a considerable number of diagnoses with no recorded ethnicity. As a percentage of cases where ethnicity is known, 96% are in white men and 2% in black men. There is interaction between ethnicity and age, with ethnic minority populations tending to be younger on the whole. 8 There is also interaction between ethnicity and geography with 65% of cases in black men in London SCN or West Midlands SCN. Most men in the cohort had no comorbidities according to our method. The range between SCNs was 90% to 98% of cases with no comorbidities. This contrasts with other studies which concluded only half of men had no comorbidities. As such this may suggest limitations with using a Charlson score derived from routine administrative data.
Overall, 1692 (14%) of men in the cohort had a record of RP. Half of men (6212 (52%)) had a record of curative RT. Curative RT was defined as a course of 10 or more fractions. The majority of the curative RT was delivered in months 4-7 after diagnosis. The most common number of fractions was 37 (56% of men with curative RT), followed by 32 fractions (10%) and 20 fractions (7%). Uptake of radical RP varied between 9% in Wessex SCN and 20% in South West Coast SCN. Uptake of curative RT varied between 43% in Wessex SCN and 58% in East Midlands SCN, Northern England SCN and South East Coast SCN. There was no evidence that uptake of RP and radical RT was correlated. Total uptake of radical treatment varied between 52% in Wessex SCN and 73% in South East Coast SCN.
Standard practice for radical RT is delivery of one fraction on each weekday, and consequently patients must attend hospital for several weeks, with related time and monetary costs. This contrasts with a mean stay after RP of three days. Therefore we postulated that patients living further from an RT centre would be less likely to opt for RT, due to the greater inconvenience. Using postcode at diagnosis men were assigned to the group of those within 30 minutes' drive of an RT centre, or those outside that travel time.
The strongest predictor of treatment was age ( Table 1) . Each decade increase in age yielded an odds ratio (OR) of 0.39 (p < 0.001) for receiving radical treatment compared to the previous decade. This means that with each 10-year increase in age the chance of radical treatment is more than halved. No men aged 80 or over at time of diagnosis received an RP. Black men were only about half as likely as white men to receive radical treatment (OR = 0.54; p < 0.001). The OR was not as large for the RT model (OR = 0.71; p = 0.04), suggesting variation in RP uptake had a larger contribution to the model. Those whose ethnicity was unknown were more likely to receive treatment (OR = 1.19; p < 0.001). The proportion of men who had a Charlson comorbidity score of 2 or more was small at 4%, but this group had a two-thirds odds of receiving radical treatment compared to men with no comorbidities (OR = 0.66; p < 0.001). Deprivation and proximity to an RT centre were statistically significant predictors of radical treatment but with small effect sizes. Each increase in deprivation quintile led to a decrease in odds of 5% (p < 0.001). Those men who lived within 30 minutes' drive of an RT centre had an OR of 0.92 of any radical treatment (p = 0.04). The models for RP alone and RT alone suggest that this effect is related to RT, although statistical significance was not reached.
The variation observed in crude rates of RP or RT across SCNs largely disappeared once the multiple variables were accounted for.
Discussion
Unlike small-volume, low-grade prostate cancer, stage T3 and T4 disease is widely accepted as 'clinically significant'. In the absence of metastatic disease, curative intervention remains a possibility. Since publication of Bolla's data in 2002, 9 the standard of care for this group of men has taken the form of RT in combination with androgen deprivation of variable duration. This would certainly explain the higher rates of RT in this observed cohort over surgery. More recently, however, studies comparing the efficacy of radical surgery in this setting have shown some interesting results. In a study of 1238 men from the Mayo Clinic with high-risk prostate cancer (⩾ T3N0M0 PSA >20 Gleason 8-10) treated with either RP or external-beam radiotherapy (EBRT) plus androgen-deprivation therapy (ADT), no significant difference in disease-specific mortality or systemic progression was observed after a median follow-up of 10.2 years in the surgical group and 6.0 years in the RT group. 10 Indeed, an observational study of 34,515 Swedish men with follow-up to 15 years suggested that younger men with intermediate or high-risk non-metastatic disease have improved survival with surgery versus RT. 11 As a result RP (with lymph node dissection) is a recognised treatment option for locally advanced disease, as reflected in the NICE guidance. 5 RT techniques are continuing to evolve, and a combination of high-dose-rate (HDR) brachytherapy boost and EBRT have been shown to have 10-year biochemical progression-free survival (BPFS) and cancer-specific survival of 78% and 93%, respectively. 12 Therefore HDR brachytherapy and EBRT is the recommended treatment by the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology 13 for men with high-risk localised or locally advanced tumours. Newer multimodality approaches with surgery in combination with RT are also adopted with evaluation currently taking place as part of the Radiotherapy and Androgen Deprivation in Combination after Local Surgery (RADICALS) study. 14 The optimal management of men with locally advanced prostate cancer both in terms of oncological outcome and quality of life is yet to be determined. Given the recent NICE guidance we might expect the rates of surgical treatment to grow, along with a multimodality approach for increasing numbers of men.
We expect prostate cancer incidence to increase with age, although it is interesting to note the variation in the proportion of men over 80 with T3 disease by region. The greater incidence in higher socioeconomic groups is likely to be due to the increased awareness and use of opportunistic screening, but also the longer life-expectancy and hence older population in these groups. The relatively small proportion of ethnic minorities may also reflect a lack of screen-detected tumours, but is interesting to note that ethnic minority populations with T3/4 prostate cancer tended to be younger. The increased likelihood of radical treatment suggests that there may be an unaccounted for confounding in measurement of ethnicity.
Based on comorbidities data we could assume that the majority of men are fit and suitable for radical treatment. Despite that, a significant proportion did not have treatment with curative intent. It is possible that some men had other comorbidities not included in the Charlson comorbidity index which precluded radical treatment. Others may have preferred a policy of watchful waiting. Nevertheless, there is some variation by SCN. Therefore, there is a possibility that some men with 'clinically significant' disease are undertreated.
These data represent an interesting view of both the types of treatment and treatment rates for locally advanced prostate cancer. It will be interesting to observe any change in future years, perhaps with an increasing use of surgery, HDR brachytherapy and multimodality options for all age groups, particularly as the population remains medically fitter for longer. It will also be important to monitor regional variation as we strive to delivery consistency in medical care.
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